Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver.
about
Hepatitis C virus protease inhibitor-resistance mutations: our experience and reviewTelaprevir- and boceprevir-based tritherapies in real practice for F3-F4 pretreated hepatitis C virus patients.Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future?Ultradeep pyrosequencing of NS3 to predict response to triple therapy with protease inhibitors in previously treated chronic hepatitis C patients.Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: a meta-analysis on the role of response predictorsNaturally Occurring Resistance-Associated Variants of Hepatitis C Virus Protease Inhibitors in Poor Responders to Pegylated Interferon-Ribavirin.Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the FutureChronic hepatitis C genotype 1 virus: who should wait for treatment?Use of first-generation HCV protease inhibitors in patients coinfected by HIV and HCV genotype 1.How to optimize current therapy of HCV genotype 1 infection with boceprevir.Is there still a role for PEG IFN+RBV therapy in patients with HCV genotype 1?Revolution in hepatitis C antiviral therapy.Direct acting antiviral agents-based regimen for HCV recurrence after combined liver-kidney transplantation: results from the ANRS CO23 CUPILT study.Evaluation of telaprevir-containing triple therapy in the treatment of chronic hepatitis C in hemodialysed patients.Simeprevir added to peginterferon and ribavirin lessens time with fatigue, depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST-1, QUESHepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.A tool for selecting patients with a high probability of sustained virological response to peginterferon alfa-2a (40kD)/ribavirin.In routine clinical practice, few physicians use early viral kinetics to guide HCV dual therapy treatment decisions.Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study.Optimizing ribavirin exposure by therapeutic drug monitoring improves treatment response in patients with chronic hepatitis C genotype 1.Influence of healthcare-associated factors on the efficacy of hepatitis C therapyRibavirin at the Era of Novel Direct Antiviral Agents for the Treatment of Hepatitis C Virus Infection: Relevance of Pharmacological Monitoring
P2860
Q24628717-3B99FAF3-74D1-408B-935F-8EE06C9BC005Q30430083-3226934F-DA5C-42BB-825F-0794D667FFBFQ33426112-7D13707C-F300-477E-AE34-660921560DB1Q34983102-E9AA1732-8F5C-4A02-94D7-DE4B88490DFEQ35146790-681AAE51-A81E-471A-BDDC-80C240F6C398Q35757761-2A2FCD04-C975-413A-8C2F-3B4B3AFC569FQ37135584-85D411CE-937F-4486-B7BD-87B554DBA5ADQ37654449-2433209F-3C45-4ED8-B1D0-918E65605F8CQ38153794-BB68CD9C-19DC-44CD-BFC0-13D0218AFAF5Q38174241-00FE67DC-026E-4A6F-81EB-84A061E2CE7FQ38174242-90ABF82C-DB21-492D-AA6C-1CA07B31AA43Q38355069-B791CFCC-433D-416B-BE2C-019AC16591E3Q40051223-9185CA4C-5A52-4986-AEF9-E3688A417540Q40983051-455DB6B2-760B-486E-A613-31971F023142Q41610311-BC51936D-B24B-40DD-A0BC-8CA37FA8B8A9Q42204473-24D418F7-EAF3-4D4C-A2F7-8CE6F57DD2FBQ42249693-92EE810A-9868-4B1B-A411-AC747473CD18Q42254562-BEED0F05-3FFF-43FD-BB15-4D5EAE5B4164Q42264411-F0BCD18F-B108-4E00-BC9C-A8DFEF39BAB8Q42993693-493E4985-45F4-4ACF-8C33-5C8C890967B3Q56917730-A3522B72-D017-4CA9-93D1-C3CD90078B98Q59049605-E23D5544-1955-44B8-8E05-B12CF62FDE73
P2860
Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver.
description
2012 ഓഗസ്റ്റ് 14ന് പ്രസിദ്ധീകരിച്ച ശാസ്ത്ര സംബന്ധിയായ ലേഖനം
@ml
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
name
Protease inhibitor-based tripl ...... on for the Study of the Liver.
@en
type
label
Protease inhibitor-based tripl ...... on for the Study of the Liver.
@en
prefLabel
Protease inhibitor-based tripl ...... on for the Study of the Liver.
@en
P2093
P1433
P1476
Protease inhibitor-based tripl ...... on for the Study of the Liver.
@en
P2093
Alexandre Pariente
Fabien Zoulim
French Association for the Study of the Liver
Georges-Philippe Pageaux
Jean-Pierre Bronowicki
Lawrence Serfaty
Marc Bourlière
Patrick Delasalle
Vincent Leroy
P304
P356
10.1111/J.1478-3231.2012.02856.X
P577
2012-08-14T00:00:00Z